Further to the identification of isolated metabolic targets, the combination of existing GBM chemoradiation protocols with agonists/antagonists of multiple signalling pathways such as sonic hedgehog (Shh), murine double minute 2 (MDM2), p53, PI3K/mTOR, EGFRvIII, poly(ADP-ribose) polymerase 1 (PARP1), cyclin-dependent kinase 4/6 (CDK4/6) have exhibited cytotoxic sensitisation efficacy of GBM models (185–191). This evidence concerns the gene TP53 and glioblastoma.